This clinical trial is focused on studying treatments for urothelial cancer, which is a type of cancer that affects the bladder and other parts of the urinary system. The study is investigating a new treatment called BT8009, which is being tested both on its own and in combination with other medications. These medications include pembrolizumab, cisplatin, carboplatin, gemcitabine, and avelumab. The purpose of the study is to evaluate how effective BT8009 is in treating this type of cancer, either alone or when used with other drugs.
Participants in the study will receive treatments through an infusion, which means the medication is given directly into the bloodstream. The study is divided into different groups, or cohorts. In one group, BT8009 will be combined with pembrolizumab and compared to standard chemotherapy treatments, which may include cisplatin or carboplatin with gemcitabine, and possibly avelumab. In another group, BT8009 will be given alone to see how well it works by itself. The study will monitor how the cancer responds to these treatments over time.
The trial aims to understand how these treatments affect the progression of the cancer and the overall response of the participants. The study will last for several months, with regular check-ups to assess the effectiveness of the treatment. Participants will be closely monitored by medical professionals throughout the study to ensure their safety and to gather important data on the treatments being tested.
Spain 
